Yinhua CNI HK Connect Innovative Drugs ETF

CSPC PHARMA FY2026 Q1 Earnings Release on May 27 Pre-Market (BJT), Forecast Revenue HKD 7.905 B, EPS HKD 0.102

National Healthcare Security Administration Adjusts 2026 Catalog Plan, Strengthening Market Expectations for Innovative Drugs

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

CSPC's SYH2095 receives clinical trial approval and FDA clearance, trials set to begin in April 2026

China Biopharma spends 10 million HKD to repurchase 1.89 million shares on May 18

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

China Biopharma spends 10.0269 million HKD to repurchase 1.87 million shares

Zhongtai Securities lowers Sanhome's earnings forecast and maintains Buy rating

BeiGene's Brukinsa Approved by FDA

China Biopharmaceutical Announces Preclinical Results of Obesity Treatment Candidate TQF6422

Hanson Pharma Group Begins HS-10541 Clinical Trial with NMPA Approval

China Bio-Pharmaceuticals repurchased 1.78 million shares

Sichuan Kelun Biotech Obtains Approval to Begin Clinical Trials for PD-1xVEGF Bispecific Antibody SKB118

CStone Pharmaceuticals Reaps Significant Benefits from 707 Authorization Deal with Pfizer

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

Jade Pharmaceutical's SYS6010 Enters Phase 3 Clinical Trials for Esophageal Squamous Cell Carcinoma

China Biopharmaceutical bought back 1.81 million shares for HKD10.0149 million

China BioPharmaceuticals repurchasing 1.81 million shares

CMBC International and DBS Maintain Buy Rating for BeiGene

Jiayi Group's BD Project MAT2A Inhibitor Downgraded by BeiGene

159567

The Yinhua CNI HK Connect Innovative Drugs ETF (159567) received a net financing purchase of CNY 7.0121 million on May 19, with a net financing purchase of CNY 32.0927 million in the past week and CNY 18.4732 million in the past month. This ETF was listed on January 11, 2024, and is managed by Yinhua Fund, with the latest fund size being CNY 7.45 billion

同壁财经

On May 19th, the Yinhua CNI HK Connect Innovative Drugs ETF (159567) had a net financing purchase of RMB 7.0121 million, with a net financing purchase of RMB 32.0927 million in the past week

01952

588130

159992

516500

520880

159316

159849

159506

159570

520690

512290

510660

516930

159892

On May 14, 2026, Wei Fu, a substantial shareholder of Everest Medicines, purchased 660,000 shares for approximately HK$20.7 million, marking his second acquisition this year. His previous purchase was on March 27, acquiring 860,000 shares. These actions reflect his confidence in the company's strategic direction and operational achievements, as Everest aims for over RMB15 billion in revenue by 2030. The company reported a 142% revenue increase in 2025, achieving profitability for the first time and strong sales in its innovative drugs.

Asian Corporate Newswire

EVEREST MED

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence

Everest Medicines Ltd. announced that non-executive director Wei Fu has increased his stake by purchasing 660,000 shares for approximately HK$20.7 million, averaging HK$31.25 per share. This move reflects Fu's confidence in the company's future, with potential for further increases in holdings. However, the board advises caution to investors. The latest analyst rating for Everest Medicines (HK:1952) is a Hold, with a price target of HK$55.00. Everest Medicines focuses on developing innovative medicines for unmet medical needs and has a market cap of HK$11.36B.

Tip Ranks

Everest Medicines Director and Major Shareholder Raises Stake in Company

516820

Everest Medicines announced positive first-in-human data for its personalized mRNA cancer vaccine, EVM16, at the AACR 2026. The trial showed EVM16 has a favorable safety profile and promising preliminary efficacy in patients with advanced solid tumors. Results indicated strong T cell responses and some patients achieved partial responses or stable disease after failing multiple therapies. The vaccine is powered by Everest's AI-based neoantigen prediction algorithm, aiming to expand treatment options for patients with limited therapies available. The company plans to continue advancing EVM16's clinical development.

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

Everest Medicines Announces Positive First-in-Human Data for Personalized mRNA Cancer Vaccine EVM16 at AACR 2026

800医药

515120

517380

159858

In the first quarter of 2026, China's innovative drug industry performed exceptionally well, with the total amount of out-licensing transactions exceeding USD 60 billion, nearly half of the total for the entire year of 2025. The National Medical Products Administration approved 13 innovative drugs for market launch, of which 6 are first-in-class drugs, covering key disease areas. The total number of innovative drugs under research in China reached 4,751, accounting for 33.7% of the global total, with over 45% in several cutting-edge fields. China has become the world's largest country for innovative drugs under research, with transaction volume accounting for 49% of the global total

腾讯新闻 - 财经

GF CSI Innovative Drugs Industry ETF

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

E Fund CSI Innovative Drugs ETF

ICBCCS CSI Brand Name Drug Industry ETF

CCB Principal CSI Innovative Drugs Industry ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

China Southern CSI Brand Name Drug Industry ETF

JPMorgan Chase

INNOVENT BIO

Eli Lilly

CSPC PHARMA

AstraZeneca

CITIC Securities Co., Ltd.

CITIC SEC

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

AstraZeneca PLC

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

EverSea Medicines, a subsidiary of Everest Medicines, has signed a share purchase agreement to acquire Hasten Biopharmaceuticals for $250 million. The deal includes MAH rights, trademarks, and commercial rights for 14 chronic disease products in the Asia Pacific region. The acquisition aims to enhance Everest Medicines' market presence and commercial capabilities. Hasten Biopharmaceuticals reported normalized revenue of $82.23 million and EBITDA of $27.27 million in December 2025. The acquisition is expected to expedite product commercialization and support international growth.

Pharmaceutical Technology

Bosera Hang Seng Health Care ETF(QDII)

EverSea Medicines to acquire Hasten Biopharmaceuticals

Everest Medicines is set to acquire Hasten Biopharmaceuticals for US$250 million, gaining rights to 14 chronic-disease treatments in the Asia-Pacific region. This acquisition, which includes a US$148.8 million shareholder loan, reflects a growing trend of global investment in China's biopharmaceutical sector. The deal comes as cross-border out-licensing by Chinese drugmakers reached a record US$60 billion in Q1 2023, driven by demand for early-stage assets. Additionally, Syneron Bio raised US$150 million to advance its AI-driven drug development platform, highlighting the increasing interest in innovative biotech solutions.

SCMP

Everest’s US$250 million buy signals rising global appetite for China biotech

513130

589850

The situation between the U.S. and Iran has eased, and Trump has agreed to suspend attacks on Iran, leading to a rebound in global risk assets. The market is focusing on three major investment directions: 1) undervalued assets, such as Hang Seng Technology ETF and innovative drugs ETF; 2) oversold small-cap growth stocks, such as Science and Technology Innovation Board 200 ETF; 3) growth sectors with upward revisions in performance, paying attention to STAR 50 ETF and semiconductor equipment ETF. Medium to long-term investors can increase equity positions through SSE Index ETF to seize market opportunities

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

Eastmoney Fund SSE Science and Technology Innovation Board 50 ETF

CSOP STAR 50

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

ICBCCS SZSE ChiNext 50 ETF

Penghua SSE Science and Technology Innovation Board 50 ETF

Guotai CES Semiconductor Chip Industry ETF

Hang Seng TECH Index

Fullgoal SSE Composite ETF

Hang Seng TECH ETF I

Guotai SSE Composite ETF

Huatai-PB SSE Science and Technology Innovation Board 200 ETF

First Trust NYSE Arca Biotech Index Fd

Guotai SSE Science and Technology Innovation Board 200 ETF

Tianhong Hang Seng TECH ETF(QDII)

GF Fund SSE Science and Technology Innovation Board 200 ETF

GTJA Allianz SSE STAR Chip Design Thematic ETF

Dacheng Hang Seng Technology ETF(QDII)

SSE Index

Fullgoal SSE Science and Technology Innovation Board 200 ETF

The situation between the US and Iran has eased, risk appetite has warmed, and three main lines are grasping the rebound opportunities

Yinhua CNI HK Connect Innovative Drugs ETF(159567.SZ)